| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02781311 | A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males | PHASE2 | COMPLETED | 169 | — | — | Jul 14, 2016 | May 22, 2018 | Apr 5, 2019 | 18 | United States |
TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters square (cm\^2). TAHC is a standardized objective quantification of the number of hairs within a prespecified target area of the scalp at different timepoints, using macrophotography digital images. The total number of terminal hairs (hair width ≥ 30 μm) was calculated from macrophotographs. The target area used to count TAHC was a 1 cm\^2 circular area of clipped hair (length approximately 1 mm) located at the anterior leading edge of the vertex thinning area of the scalp and centered with a semi-permanent microdot tattoo to ensure the same target area was reproduced at each visit. A positive change from Baseline indicated improvement (increase in the number of terminal hairs). Missing data are imputed up to Week 24 using last observation carried forward (LOCF) method.
The SSA consisted of a single-item measure that assesses each participant's perception of change in scalp hair growth. The participant used a standardized global photograph of his scalp taken at the Screening visit presented side by side with a standardized global photograph taken at the postbaseline visit to give a comparative score. The photographs were presented in a blinded and randomized manner to avoid influencing the participant, and response options were on a 7-point ordinal scale (where, -3=Greatly decreased, -2=Moderately decreased, -1=Slightly decreased, 0=No change, +1=Slightly increased, +2=Moderately increased and +3=Greatly increased). The higher the mean SSA value, the more the perception of hair growth from baseline. Missing data are imputed up to Week 24 using LOCF method.
| Arm | Type | Description |
|---|---|---|
| Setipiprant | EXPERIMENTAL | Setipiprant 1000 mg (2 X 500 mg) tablets, orally, BID at 12-hour intervals for 24 weeks. |
| Placebo | PLACEBO_COMPARATOR | Two placebo tablets BID at 12-hour intervals for 24 weeks. |
| Finasteride | ACTIVE_COMPARATOR | Finasteride 1 mg tablet, orally, once daily for 24 weeks. |
| Name | Type | Description |
|---|---|---|
| Setipiprant | DRUG | Setipiprant tablets, orally, BID for 24 weeks. |
| Placebo | DRUG | Placebo tablets, orally, BID for 24 weeks. |
| Finasteride | DRUG | Finasteride tablet, orally, once daily for 24 weeks. |
Inclusion Criteria: * Participant has androgenetic alopecia (AGA) * Participant agrees to maintain current hair care regimen, refraining from hair weaving, hair colorants or dyes and non-study hair growth products during the study. Exclusion Criteria: * History of hair loss for reasons other than...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | Ritlecitinib, Ritlecitinib higher dose, LITFULO, Litfulo |
| Veradermics, Incorporated | MANE | 4 | PHASE3 | VDPHL01 |
| AbbVie, Inc. | ABBV | 3 | PHASE3 | Upadacitinib |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Baricitinib, LY4005130 |
| ICON Plc | ICLR | 1 | PHASE3 | Clascoterone 5%, Vehicle |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE2 | Amlitelimab |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | bempikibart |
| Absci Corporation | ABSI | 1 | PHASE1 | ABS-201 Single Dose, ABS-201 Multiple Doses |
| Forte Biosciences Inc. | FBRX | 1 | PHASE1 | FB102 |
| HCW Biologics, Inc. | HCWB | 1 | PHASE1 | HCW9302, an IL-2 fusion protein |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | Dupilumab |